{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:43:10Z","timestamp":1777045390891,"version":"3.51.4"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":434,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>On the basis of recent clinical trial data for the treatment of drug-susceptible and drug-resistant tuberculosis (TB), the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America have updated clinical practice guidelines for TB treatment in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Joint Panel representing multiple interdisciplinary perspectives convened with American Thoracic Society methodologists to review evidence and make recommendations using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) and GRADE-ADOLOPMENT (adoption, adaptation, and, as needed, de novo development of recommendations) methodology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>New drug-susceptible TB recommendations include the use of a novel 4-month regimen for people with pulmonary TB and a shortened 4-month regimen for children with nonsevere TB. Drug-resistant TB recommendation updates include the use of novel regimens containing bedaquiline, pretomanid, and linezolid with or without moxifloxacin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>All-oral, shorter treatment regimens for TB are now recommended for use in eligible individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202410-2096st","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T09:31:56Z","timestamp":1735551116000},"page":"15-33","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":94,"title":["Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS\/CDC\/ERS\/IDSA Clinical Practice Guideline"],"prefix":"10.1093","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4200-315X","authenticated-orcid":false,"given":"Jussi J.","family":"Saukkonen","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-3099","authenticated-orcid":false,"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7493-9163","authenticated-orcid":false,"given":"Sonal S.","family":"Munsiff","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2591-1439","authenticated-orcid":false,"given":"Carla A.","family":"Winston","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0343-3234","authenticated-orcid":false,"given":"Manoj J.","family":"Mammen","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-1430","authenticated-orcid":false,"given":"Ibrahim","family":"Abubakar","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6966-5682","authenticated-orcid":false,"given":"Carlos","family":"Acu\u00f1a-Villaordu\u00f1a","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-1890","authenticated-orcid":false,"given":"Pennan M.","family":"Barry","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0582-8870","authenticated-orcid":false,"given":"Mayara L.","family":"Bastos","sequence":"additional","affiliation":[]},{"given":"Wendy","family":"Carr","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9239-2528","authenticated-orcid":false,"given":"Hassan","family":"Chami","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-0111","authenticated-orcid":false,"given":"Lisa L.","family":"Chen","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7722-0958","authenticated-orcid":false,"given":"Terence","family":"Chorba","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3324-926X","authenticated-orcid":false,"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[]},{"given":"Anthony J.","family":"Garcia-Prats","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9610-1134","authenticated-orcid":false,"given":"Kelly","family":"Holland","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-1318","authenticated-orcid":false,"given":"Ioannis","family":"Konstantinidis","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7501-4448","authenticated-orcid":false,"given":"Marc","family":"Lipman","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-574X","authenticated-orcid":false,"given":"Giovanni","family":"Battista Migliori","sequence":"additional","affiliation":[]},{"given":"Farah M.","family":"Parvez","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3106-1258","authenticated-orcid":false,"given":"Adrienne E.","family":"Shapiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1600-4474","authenticated-orcid":false,"given":"Giovanni","family":"Sotgiu","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-6697","authenticated-orcid":false,"given":"Jeffrey R.","family":"Starke","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-5623","authenticated-orcid":false,"given":"Angela M.","family":"Starks","sequence":"additional","affiliation":[]},{"given":"Sanket","family":"Thakore","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8006-2401","authenticated-orcid":false,"given":"Shu-Hua","family":"Wang","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-5290","authenticated-orcid":false,"given":"Jonathan M.","family":"Wortham","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-1311","authenticated-orcid":false,"given":"Payam","family":"Nahid","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2025,1,1]]},"reference":[{"key":"2026031105194266000_bib1","author":"World Health Organization (WHO)","year":"2022"},{"key":"2026031105194266000_bib2","author":"World Health Organization (WHO)","year":"2022"},{"key":"2026031105194266000_bib3","author":"Centers for Disease Control and Prevention (CDC)","year":"2023"},{"key":"2026031105194266000_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","article-title":"Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis\u2014United States, 2022","volume":"71","author":"Carr","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026031105194266000_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT","volume":"81","author":"Sch\u00fcnemann","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2026031105194266000_bib6","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026031105194266000_bib7","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105194266000_bib8","volume-title":"GRADEpro Guideline Development Tool","author":"Evidence Prime","year":"2024"},{"key":"2026031105194266000_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jclinepi.2011.08.001","article-title":"\u201cMight\u201d or \u201csuggest\u201d? No wording approach was clearly superior in conveying the strength of recommendation","volume":"65","author":"Akl","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"2026031105194266000_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2026031105194266000_bib11","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031105194266000_bib12","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1093\/cid\/ciac707","article-title":"Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with human immunodeficiency virus (S31\/A5349)","volume":"76","author":"Pettit","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026031105194266000_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/11531490-000000000-00000","article-title":"Safety considerations of fluoroquinolones in the elderly: an update","volume":"27","author":"Stahlmann","year":"2010","journal-title":"Drugs Aging"},{"key":"2026031105194266000_bib14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1513\/AnnalsATS.201704-326OC","article-title":"Exposure to latent tuberculosis treatment during pregnancy. The PREVENT TB and the iAdhere trials","volume":"15","author":"Moro","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2026031105194266000_bib15","first-page":"1196","author":"Sterling","year":"2020"},{"key":"2026031105194266000_bib16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2104535","article-title":"Shorter treatment for nonsevere tuberculosis in African and Indian children","volume":"386","author":"Turkova","year":"2022","journal-title":"N Engl J Med"},{"key":"2026031105194266000_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5588\/pha.17.0091","article-title":"The California multidrug-resistant tuberculosis consult service: a partnership of state and local programs","volume":"8","author":"Shah","year":"2018","journal-title":"Public Health Action"},{"key":"2026031105194266000_bib18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2026031105194266000_bib19","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"key":"2026031105194266000_bib20","author":"World Health Organization (WHO)","year":"2022"},{"key":"2026031105194266000_bib21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.5588\/ijtld.21.0022","article-title":"Bedaquiline for multidrug-resistant TB in paediatric patients","volume":"25","author":"Moodliar","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026031105194266000_bib22","doi-asserted-by":"crossref","first-page":"e1002789","DOI":"10.1371\/journal.pmed.1002789","article-title":"Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: combined data from two prospective observational studies","volume":"16","author":"Garcia-Prats","year":"2019","journal-title":"PLoS Med"},{"key":"2026031105194266000_bib23","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/cid\/ciad051","article-title":"Analysis of dynamic efficacy endpoints of the Nix-TB Trial","volume":"76","author":"Solans","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026031105194266000_bib24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/cid\/ciad312","article-title":"Implementation of bedaquiline, pretomanid, and linezolid in the United States: experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant tuberculosis disease","volume":"77","author":"Haley","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026031105194266000_bib25","author":"U.S. Food and Drug Administration (FDA)","year":"2023"},{"key":"2026031105194266000_bib26","author":"Janssen Science","year":"2024"},{"key":"2026031105194266000_bib27","doi-asserted-by":"crossref","first-page":"11760","DOI":"10.1038\/s41598-019-48289-9","article-title":"Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations","volume":"9","author":"Rigouts","year":"2019","journal-title":"Sci Rep"},{"key":"2026031105194266000_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12941-021-00478-z","article-title":"Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis","volume":"20","author":"Ye","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2026031105194266000_bib29","author":"UCSF"},{"key":"2026031105194266000_bib30","author":"World Health Organization (WHO)","year":"2021"},{"key":"2026031105194266000_bib31","author":"World Health Organization (WHO)","year":"2018"},{"key":"2026031105194266000_bib32","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","article-title":"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid","volume":"75","author":"Kadura","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026031105194266000_bib33","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine"},{"key":"2026031105194266000_bib34","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.3390\/antibiotics11111586","article-title":"A dual perspective of psycho-social barriers and challenges experienced by drug-resistant TB patients and their caregivers through the course of diagnosis and treatment: findings from a qualitative study in Bengaluru and Hyderabad Districts of South India","volume":"11","author":"Nagarajan","year":"2022","journal-title":"Antibiotics"},{"key":"2026031105194266000_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2458-14-46","article-title":"The importance of providing counselling and financial support to patients receiving treatment for multi-drug resistant TB: mixed method qualitative and pilot intervention studies","volume":"14","author":"Baral","year":"2014","journal-title":"BMC Public Health"},{"key":"2026031105194266000_bib36","doi-asserted-by":"crossref","first-page":"e0147397","DOI":"10.1371\/journal.pone.0147397","article-title":"Psycho-socio-economic issues challenging multidrug resistant tuberculosis patients: a systematic review","volume":"11","author":"Thomas","year":"2016","journal-title":"PLoS One"},{"key":"2026031105194266000_bib37","doi-asserted-by":"crossref","first-page":"e0001337","DOI":"10.1371\/journal.pgph.0001337","article-title":"Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis","volume":"2","author":"Sweeney","year":"2022","journal-title":"PLoS Glob Public Health"},{"key":"2026031105194266000_bib38","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation\u2019s direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2026031105194266000_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1164\/rccm.202010-3943ST","article-title":"Informing healthcare decisions with observational research assessing causal effect. An official American Thoracic Society research statement","volume":"203","author":"Gershon","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105194266000_bib40","article-title":"Reported tuberculosis in the United States, 2023 [accessed 2024 Nov 19]","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"2026031105194266000_bib41","article-title":"Tuberculosis surveillance and monitoring in Europe 2022\u20142020 data","author":"European Centre for Disease Prevention and Control and World Health Organization","year":"2022"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/1\/15\/67292592\/ajrccm_211_1_15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/1\/15\/67292592\/ajrccm_211_1_15.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:19:50Z","timestamp":1773220790000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/211\/1\/15\/8513358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]},"published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202410-2096st","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1,1]]},"assertion":[{"value":"2024-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}